Is Trastuzumab included in medical insurance?

The original drug Trastuzumab (Trastuzumab) is marketed and sold in China under the trade name Herceptin and has entered the scope of Class B medical insurance. However, the purchase may be limited to patients who meet the indications of this drug, such as HER2-positive metastatic breast cancer and its adjuvant and neoadjuvant treatment or HER2-positive metastatic gastric cancer. The price is about 6,000 yuan.

Trastuzumab is a targeted cancer drug called a monoclonal antibody. It is a treatment for cancers that contain large amounts of a protein called human epidermal growth factor receptor2 (HER2). It is suitable for early-stage breast cancer (where the cancer has not spread to the breast). Trastuzumab blocks the growth and division of cancer cells by attaching to HER2, binding to the HER2 receptor and slowing cell replication in patients with breast cancer, stomach cancer, and gastroesophageal junction cancer (advanced or metastatic cancer) that have spread to other parts of the body.

When given as an intravenous infusion, trastuzumab is administered weekly or every three weeks for breast cancer over 90 minutes or every three weeks for gastric cancer. Common side effects of trastuzumab include fever, infection, cough, headache, insomnia, and rash. Other serious side effects include heart failure, allergic reactions, and lung disease. Use during pregnancy may harm the baby. The original trastuzumab drug has also been launched overseas. The ingredients of domestic and foreign original drugs are basically the same. For specific prices and drug details, you can consult a medical consultant. Currently, there are no generic trastuzumab drugs on the market.